A Service For Professionals Sunday, December 17, 2017
Contact (202) 540-8337
World News Report
A Service For Professionals Sunday, December 17, 2017 11610 Sources 421,847,528 Articles 2,875,095 Readers
Contact (202) 540-8337

Message from Pfizer Senior Director, Head of Medicinal Chemistry

Advances & Progress in Drug Design

Advances & Progress in Drug Design

John Mathias, Senior Director, Head of Medicinal Chemistry at Pfizer, to chair 13th annual conference on Advances and Progress in Drug Design.

Advances & Progress in Drug Design offers an unparalleled snapshot of current trends and future horizons in drug design”
— John Mathias, Pfizer

LONDON, LONDON, UNITED KINGDOM, February 3, 2014 /EINPresswire.com/ -- In just 2 weeks time, the highly anticipated conference on Advances and Progress in Drug Design, will return to London and open its doors to leading pioneers from across the globe to discuss, debate and share ideas and challenges facing the drug design arena. Key areas to be addressed will include structure based drug design, water applications, fragment based drug design, lead optimisation challenges and molecular design. Download the agenda here.

Due to high demand, SMi Group Ltd have announced that availability to attend the 13th annual instalment is now strictly limited. Registration will be closing soon. Those who are interested can still register online at www.drug-design.co.uk

Conference chairman John Mathias, Senior Director and Head of Medicinal Chemistry at Pfizer, commented:

“Advances & Progress in Drug Design offers an unparalleled snapshot of current trends and future horizons in drug design. Bringing together leaders in the fields of computational, structural & biophysical methods to showcase applications across a wide range of target classes, at every stage of the drug discovery process, the meeting offers a unique opportunity to share and debate the best strategies to improve drug discovery going forward and discuss diverse questions such as the status of fragment-based lead optimization, current hit identification methods and the potential of epigenetic-target based discovery.”

Key note addresses will include presentations from D. E. Shaw Research, Pfizer, Roche, MedImmune, Astex Pharmaceuticals, Bayer, Sanofi-Aventis and Novartis. Click here to view full speaker line up and conference agenda.

Advances and Progress in Drug Design:
Delivering Practical Solutions to Drug Delivery Challenges
17-18 February 2014
Marriott Regents Park Hotel, London UK
www.drug-design.co.uk

About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.
We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.
More information can be found at www.smi-online.co.uk

Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
email us here

Powered by EIN Presswire